Skip to content

Pneumonia Due to Stenotrophomonas Maltophilia in ICUs

Pneumonia Due to Stenotrophomonas Maltophilia in Intensive Care Units: a Multicentre Retrospective Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03506191
Acronym
RETROSTENO
Enrollment
300
Registered
2018-04-24
Start date
2017-01-01
Completion date
2018-09-30
Last updated
2018-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Pneumonia, Bacterial, Pneumonia, Ventilator-Associated, Stenotrophomonas Infection

Keywords

Stenotrophomonas maltophilia, Pneumonia, Intensive Care Unit

Brief summary

Pneumonia is a major cause of ICU admission, or may complicate ICU course. Among the causative pathogens, Stenotrophomonas Maltophilia is a rare pathogen, but affects usually patients with chronic pulmonary co-morbidities, or with long duration of mechanical ventilation and multiples treatment with broad spectrum antimicrobial therapy. However, there are only a paucity of data regarding epidemiology, impact and outcome of Pneumonia due to Stenotrophomonas Maltophilia in critically ill patients. Primary objective was to study factors associated with mortality in case of Pneumonia due to Stenotrophomonas Maltophilia. Secondary objectives were to describe factors associated with morbidity of Pneumonia due to Stenotrophomonas Maltophilia (duration of mechanical ventilation, ICU length of stay), and to report the characteristics of critically ill patients presenting Pneumonia due to Stenotrophomonas Maltophilia.

Interventions

None listed

Sponsors

Groupe Hospitalier Pitie-Salpetriere
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients older than 18 years Documented Stenotrophomonas maltophilia pneumonia: * Clinical suspicion (≥ two criteria including: fever\> 38.5°C, leukocytosis \> 10\^9/L or leukopenia \< 4.10\^8/L, purulent tracheobronchial secretions and a new or persistent infiltrate on chest radiography). * Documented Stenotrophomonas maltophilia positive quantitative culture of a respiratory sample: bronchoalveolar lavage fluid (significant threshold, \>10\^4cfu/ml) or plugged telescopic catheter (significant threshold, \>10\^3cfu/ml) or quantitative endotracheal aspirate (significant threshold, \>10\^6cfu/ml).

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Treatment failureDay 30Treatment failure is defined as composite of death and recurrence of pneumonia due to Stenotrophomonas Maltophilia within 30 days of the first episode

Secondary

MeasureTime frameDescription
Duration of mechanical ventilationDay 30Number of days under mechanical ventilation
Recurrence of pneumonia due to Stenotrophomonas MaltophiliaDay 30New onset of pneumonia due to Stenotrophomonas Maltophilia
MortalityDay 30

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026